-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMI-2007 in Herpes Zoster (Shingles)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMI-2007 in Herpes Zoster (Shingles) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMI-2007 in Herpes Zoster (Shingles) Drug Details: BMI-2007 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotagliflozin in Hypertrophic Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotagliflozin in Hypertrophic Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotagliflozin in Hypertrophic Cardiomyopathy Drug Details: Sotagliflozin (Zynquista, Inpefa) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotagliflozin in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotagliflozin in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotagliflozin in Type 2 Diabetes Drug Details: Sotagliflozin (Zynquista, Inpefa)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tirzepatide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tirzepatide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tirzepatide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Tirzepatide...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewHyaluronic Acid Fillers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hyaluronic Acid Fillers Pipeline Market Report Overview Hyaluronic Acid (HA) is a glycosaminoglycan disaccharide, which exists naturally in the body. Approximately 50% of the total HA is found in the skin. Injections of HA are used for reducing wrinkles in the face and for soft tissue augmentation. The hyaluronic acid fillers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the...
-
Product Insights
Herpes Zoster (Shingles) – Drugs In Development, 2023
Global Markets Direct’s, ‘Herpes Zoster (Shingles) - Drugs In Development, 2023’, provides an overview of the Herpes Zoster (Shingles) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Varicella Zoster (HHV-3) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Drugs In Development, 2023’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saxenda in Smoking Cessation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Saxenda in Smoking CessationDrug Details:Liraglutide (Saxenda) an analog of human GLP-1 acts as an antiobesity agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Bupropion Hydrochloride + Naltrexone) Er in Smoking Cessation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Bupropion Hydrochloride + Naltrexone) Er in Smoking CessationDrug Details:Bupropion hydrochloride and Naltrexone (Contrave, Mysimba) is a...